The Potential Protective Role of Peripheral Immunophenotypes in Alzheimer's Disease: a Mendelian Randomization Study

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2024 Jun 21

PMID 38903900

Authors

Chun-Yan Zuo

Zhengwei Hu

Xiao-Yan Hao

Meng-Jie Li

Jing-Jing Shi

Meng-Nan Guo

Dong-Rui Ma

Shuang-Jie Li

Yuan-Yuan Liang

Chan Zhang

Cheng-Yuan Mao

Yuming Xu

Chang-He Shi

Affiliations

Soon will be listed here.

Abstract

Introduction: Alzheimer's disease (AD) is the most widespread neurodegenerative disease in the world. Previous studies have shown that peripheral immune dysregulation plays a paramount role in AD, but whether there is a protective causal relationship between peripheral immunophenotypes and AD risk remains ambiguous.

Methods: Two-sample Mendelian randomization (MR) was performed using large genome-wide association study (GWAS) genetic data to assess causal effects between peripheral immunophenotypes and AD risk. Utilizing the genetic associations of 731 immune cell traits as exposures. We adopted the inverse variance weighted method as the primary approach. The Weighted median and MR-Egger regression methods were employed as supplements. Various sensitivity analyses were performed to assess the robustness of the outcomes.

Results: Based on the IVW method, we identified 14 immune cell traits that significantly reduced the risk of AD, of which six demonstrated statistical significance in both IVW and Weighted median methods. Among the seven immune traits, four were related to regulatory T (Treg) cells : (1) CD25++ CD45RA- CD4 not regulatory T cell % T cell (odds ratio (OR) [95% confidence interval (CI)] = 0.96 [0.95, 0.98], adjusted = 1.17E-02), (2) CD25++ CD45RA- CD4 not regulatory T cell % CD4+ T cell (OR [95% CI] = 0.97 [0.96, 0.99], adjusted = 3.77E-02), (3) Secreting CD4 regulatory T cell % CD4 regulatory T cell (OR [95% CI] = 0.98 [0.97, 0.99], adjusted = 7.10E-03), (4) Activated & secreting CD4 regulatory T cell % CD4 regulatory T cell(OR [95% CI] = 0.98 [0.97, 0.99], adjusted = 7.10E-03). In addition, HLA DR++ monocyte % monocyte (OR [95% CI] = 0.93 [0.89, 0.98], adjusted = 4.87E-02) was associated with monocytes, and HLA DR on myeloid Dendritic Cell (OR [95% CI] = 0.93 [0.89, 0.97], adjusted = 1.17E-02) was related to dendritic cells (DCs).

Conclusion: These findings enhance the comprehension of the protective role of peripheral immunity in AD and provide further support for Treg and monocyte as potential targets for immunotherapy in AD.

References

Bellenguez C, Kucukali F, Jansen I, Kleineidam L, Moreno-Grau S, Amin N . New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022; 54(4):412-436. PMC: 9005347. DOI: 10.1038/s41588-022-01024-z. View

Saraiva M, OGarra A . The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010; 10(3):170-81. DOI: 10.1038/nri2711. View

Kamat M, Blackshaw J, Young R, Surendran P, Burgess S, Danesh J . PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics. 2019; 35(22):4851-4853. PMC: 6853652. DOI: 10.1093/bioinformatics/btz469. View

Alves S, Churlaud G, Audrain M, Michaelsen-Preusse K, Fol R, Souchet B . Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice. Brain. 2016; 140(3):826-842. DOI: 10.1093/brain/aww330. View

Glymour M, Tchetgen Tchetgen E, Robins J . Credible Mendelian randomization studies: approaches for evaluating the instrumental variable assumptions. Am J Epidemiol. 2012; 175(4):332-9. PMC: 3366596. DOI: 10.1093/aje/kwr323. View

Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart D . Nomenclature of monocytes and dendritic cells in blood. Blood. 2010; 116(16):e74-80. DOI: 10.1182/blood-2010-02-258558. View

Lawlor D, Harbord R, Sterne J, Timpson N, Davey Smith G . Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2007; 27(8):1133-63. DOI: 10.1002/sim.3034. View

Lueg G, Gross C, Lohmann H, Johnen A, Kemmling A, Deppe M . Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiol Aging. 2014; 36(1):81-9. DOI: 10.1016/j.neurobiolaging.2014.08.008. View

Aries M, Hensley-McBain T . Neutrophils as a potential therapeutic target in Alzheimer's disease. Front Immunol. 2023; 14:1123149. PMC: 10020508. DOI: 10.3389/fimmu.2023.1123149. View

10.

Ziegler-Heitbrock L . The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2006; 81(3):584-92. DOI: 10.1189/jlb.0806510. View

11.

Bowden J, Davey Smith G, Haycock P, Burgess S . Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016; 40(4):304-14. PMC: 4849733. DOI: 10.1002/gepi.21965. View

12.

Lambert J, Ibrahim-Verbaas C, Harold D, Naj A, Sims R, Bellenguez C . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013; 45(12):1452-8. PMC: 3896259. DOI: 10.1038/ng.2802. View

13.

Hemonnot A, Hua J, Ulmann L, Hirbec H . Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities. Front Aging Neurosci. 2019; 11:233. PMC: 6730262. DOI: 10.3389/fnagi.2019.00233. View

14.

Wilcock D, Rojiani A, Rosenthal A, Subbarao S, Freeman M, Gordon M . Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004; 1(1):24. PMC: 539292. DOI: 10.1186/1742-2094-1-24. View

15.

Serrano-Pozo A, Frosch M, Masliah E, Hyman B . Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2012; 1(1):a006189. PMC: 3234452. DOI: 10.1101/cshperspect.a006189. View

16.

Lykhopiy V, Malviya V, Humblet-Baron S, Schlenner S . "IL-2 immunotherapy for targeting regulatory T cells in autoimmunity". Genes Immun. 2023; 24(5):248-262. PMC: 10575774. DOI: 10.1038/s41435-023-00221-y. View

17.

Ciaramella A, Salani F, Bizzoni F, Orfei M, Caltagirone C, Spalletta G . Myeloid dendritic cells are decreased in peripheral blood of Alzheimer's disease patients in association with disease progression and severity of depressive symptoms. J Neuroinflammation. 2016; 13:18. PMC: 4727381. DOI: 10.1186/s12974-016-0483-0. View

18.

Hartwig F, Davies N, Hemani G, Davey Smith G . Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol. 2017; 45(6):1717-1726. PMC: 5722032. DOI: 10.1093/ije/dyx028. View

19.

Sperling R, Salloway S, Brooks D, Tampieri D, Barakos J, Fox N . Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012; 11(3):241-9. PMC: 4063417. DOI: 10.1016/S1474-4422(12)70015-7. View

20.

Bowden J, Del Greco M F, Minelli C, Zhao Q, Lawlor D, Sheehan N . Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption. Int J Epidemiol. 2018; 48(3):728-742. PMC: 6659376. DOI: 10.1093/ije/dyy258. View